PlexBio Co., Ltd. (TPEX:6572)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
11.10
+1.36 (13.96%)
Apr 29, 2026, 1:58 PM CST
18.84%
Market Cap 1.15B
Revenue (ttm) 127.10M
Net Income (ttm) -62.47M
Shares Out 103.65M
EPS (ttm) -0.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 978,953
Average Volume 1,200,784
Open 9.74
Previous Close 9.74
Day's Range 9.47 - 12.25
52-Week Range 5.16 - 15.80
Beta 0.44
RSI 53.93
Earnings Date May 4, 2026

About PlexBio

PlexBio Co., Ltd. develops and manufactures in vitro diagnostic reagents for molecular biology and immunology projects. It offers workflow navigation services; automated sample preparation kits; IntelliPlex platform that is designed for πCode technology with throughput sample-to-answer multiplexing assays; oncology assays, a portfolio for advanced molecular testing; and πCode coupling buffer sets. PlexBio Co., Ltd. was founded in 2009 and is based in Taipei, Taiwan. [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2009
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6572
Full Company Profile

Financial Performance

In 2025, PlexBio's revenue was 127.10 million, a decrease of -0.76% compared to the previous year's 128.06 million. Losses were -62.47 million, 1.36% more than in 2024.

Financial Statements

News

There is no news available yet.